FDA panel favors Pfizer's Prevnar 13 for expanded use

An FDA advisory panel backed Pfizer's ($PFE) Prevnar 13 vaccine for use in adults age 50 and older to stave off pneumonia, meningitis, and other pneumococcal infections. The committee voted 14-1 in favor of the new indication, and the FDA plans to make its final decision in January. Report

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.